Market-Moving News for June 17th
$BBY
$QTTB
$ZYME
Consumer Electronics/Video Chains
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/2/2026 | $76.00 | Overweight → Neutral | Analyst | |
| 12/12/2025 | $33.00 | Equal Weight → Overweight | Wells Fargo | |
| 12/3/2025 | $32.00 | Mkt Outperform | Citizens JMP | |
| 11/26/2025 | $90.00 → $95.00 | Outperform | Telsey Advisory Group | |
| 10/24/2025 | $15.00 | Equal Weight | Wells Fargo | |
| 10/14/2025 | $26.00 | Neutral → Buy | H.C. Wainwright | |
| 10/10/2025 | $30.00 | Buy | B. Riley Securities | |
| 7/14/2025 | $75.00 | Overweight → Neutral | Piper Sandler |
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
144 - Zymeworks Inc. (0001937653) (Subject)
144 - Zymeworks Inc. (0001937653) (Subject)
144 - Zymeworks Inc. (0001937653) (Subject)
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2026 Virtual Oncology Leadership Summit: Zymeworks' management will participate in one-on-one meetings February 18-19, 2026 virtually.TD Cowen 46th Annual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on March 2, 2026 at 14:30 pm – 15:00 pm Eastern Time (ET) in Boston, MA.Leerink Annu
Investment industry veteran Mr. Brian Cherry appointed to Board of DirectorsDr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating OfficerFive new Vice Presidents appointed, underscoring our commitment to leadership development VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen t
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and ChinaCompany well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation$125.0 million share repurchase plan announced in November 2025 available to reduce share countCash, cash equivalents, and marketable securities of approximately $270.6 million (unaudited) as of December
Analyst downgraded Best Buy from Overweight to Neutral and set a new price target of $76.00
Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00
Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00
3 - Zymeworks Inc. (0001937653) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
Best Buy Co., Inc. has appointed Dylan Jadeja, the chief executive officer of Riot Games, to its Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201489132/en/Dylan Jadeja (Credit: Riot Games, Inc.) Jadeja has served as the chief executive officer of Riot Games since July 2023 and has been a member of its executive team for more than a decade. Riot Games, a prominent video game developer and publisher, was founded in 2006 with the goal to create and support the most player-focused games in the world. One of the company's most well-known titles, "League of Legends," is a prime example of
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also
SC 13G/A - Zymeworks Inc. (0001937653) (Subject)
SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)
SC 13G/A - Zymeworks Inc. (0001937653) (Subject)
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales -- -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: A
The Board of Directors of Best Buy Co., Inc. (NYSE:BBY) has authorized the payment of a regular quarterly cash dividend of $0.95 per common share. The quarterly dividend is payable on January 6, 2026, to shareholders of record as of the close of business on December 16, 2025. The company had 210,052,339 shares of common stock issued and outstanding as of November 1, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20251125795144/en/ Investor Contact: Mollie O'Brien [email protected] Media Contact: Carly Charlson [email protected]